Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors.
Satoh T, Okamoto I, Miyazaki M, Morinaga R, Tsuya A, Hasegawa Y, Terashima M, Ueda S, Fukuoka M, Ariyoshi Y, Saito T, Masuda N, Watanabe H, Taguchi T, Kakihara T, Aoyama Y, Hashimoto Y, Nakagawa K.
Satoh T, et al. Among authors: hasegawa y.
Clin Cancer Res. 2009 Jun 1;15(11):3872-80. doi: 10.1158/1078-0432.CCR-08-1946. Epub 2009 May 26.
Clin Cancer Res. 2009.
PMID: 19470738
Clinical Trial.